Cotinga Pharmaceuticals Beta
Was ist das Beta von Cotinga Pharmaceuticals?
Beta von Cotinga Pharmaceuticals, Inc. ist 1.62
Was ist die Definition von Beta?
BETA gibt an, ob eine Aktie mehr oder weniger schwankungsanfällig ist als der Gesamtmarkt. Ein Beta von weniger als 1 zeigt an, dass die Aktie weniger schwankungsanfällig ist als der Markt, während ein Beta von mehr als 1 anzeigt, dass die Aktie mehr schwankungsanfällig ist. Die Schwankungsanfälligkeit wird als Schwankung des Preises um den Mittelwert gemessen.
Beta is a measure of the risk arising from exposure to general market movements as opposed to idiosyncratic factors. The market portfolio of all investable assets has a beta of exactly 1. A beta below 1 can indicate either an investment with lower volatility than the market, or a volatile investment whose price movements are not highly correlated with the market. A beta greater than one generally means that the asset both is volatile and tends to move up and down with the market. Beta is important because it measures the risk of an investment that cannot be reduced by diversification. It does not measure the risk of an investment held on a stand-alone basis, but the amount of risk the investment adds to an already-diversified portfolio. In the capital asset pricing model, beta risk is the only kind of risk for which investors should receive an expected return higher than the risk-free rate of interest.
Beta von Unternehmen in Health Care Sektor auf TSXV im Vergleich zu Cotinga Pharmaceuticals
Was macht Cotinga Pharmaceuticals?
Cotinga Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company's lead compound is COTI-2, an oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. Cotinga Pharmaceuticals Inc. has a research collaboration with St. Vincent's University Hospital to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. is based in Toronto, Canada.
Unternehmen mit beta ähnlich Cotinga Pharmaceuticals
- Royal Mail Plc hat Beta von 1.62
- Largo Resources hat Beta von 1.62
- Conifex Timber hat Beta von 1.62
- Nath Bio-Genes (India) hat Beta von 1.62
- Azimut Exploration hat Beta von 1.62
- Infineon Technologies AG hat Beta von 1.62
- Cotinga Pharmaceuticals hat Beta von 1.62
- Empired hat Beta von 1.62
- Neogenomics hat Beta von 1.62
- DBV Technologies SA hat Beta von 1.62
- Falco Resources hat Beta von 1.62
- Turquoise Hill Resources hat Beta von 1.62
- Envirosuite hat Beta von 1.62